ACell, Inc. develops and manufactures bioscaffold, extracellular matrix technology for medical and veterinary products. It offers the next generation of regenerative medicine through the development and commercialization of unique extracellular matrix devices to repair and remodel damaged tissues and organs in a broad range of surgical procedures. The firm's products include ABRA, Cytal Burn Matrix, Cytal Wound Matrix, Gentrix Surgical Matrix and MicroMatrix. It is a regenerative medicine company that focuses on the development, manufacturing and sale of products primarily used in acute care settings as part of the treatment and management of moderate to severe wounds and reinforcement of soft tissue surgical defects. The firm's products utilizes proprietary porcine urinary bladder matrix platform technology, which is designed to enhance the body's ability to restore natural tissue and minimize scarring in the management of traumatic, surgical and chronic wounds, burns, hernias and other conditions requiring the reinforcement of soft tissue. The company was founded by Stephen Xavier Graham in June 1999 and is headquartered in Columbia, MD.